All In MedTech

FDA Clearance Tracker · P050044

VITAGEL RT3 SUTGICAL HEMOSTAT

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Jun 16, 2006 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Jun 16, 2006

Approval withdrawn

Time to decision

198 days

Received Nov 30, 2005. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P050044
Device name
VITAGEL RT3 SUTGICAL HEMOSTAT
Applicant
Stryker Corp.
Applicant location
Kalamazoo, MI
Received
Nov 30, 2005
Decided
Jun 16, 2006
Decision
Approval withdrawn
Supplements
31 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III
Regulation
21 CFR 878.4490

Every decision under product code PMX

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE VITAGEL SURGICAL HEMOSTAT. THE DEVICE IS INDICATED FOR USE IN SURGICAL PROCEDURES (OTHER THAN IN NEUROSURGICAL AND OPHTHALMIC) AS AN ADJUNCT TO HEMOSTASIS WHEN CONTROL OF BLEEDING BY LIGATURE OR CONVENTIONAL PROCEDURES IS INEFFECTIVE OR IMPRACTICAL.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code PMX. The earliest in FDA's data is P990009, decided Dec 8, 1999.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Stryker Corp.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

3 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.